LENZ (LENZ Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by LENZ officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-15 | Frederic Guerard | Director | A | — | — |
| 2026-06-15 | JAMES W MCCOLLUM | Director | A | — | — |
| 2026-06-15 | Shelley B Thunen | Director | A | — | — |
| 2026-06-15 | Kimberlee C Drapkin | Director | A | — | — |
| 2026-06-15 | Zachary Scheiner | Director | A | — | — |
| 2026-06-15 | Jeffrey P. George | Director | A | — | — |
| 2026-06-15 | RA Capital Nexus Fund II, L.P. | Director | A | — | — |
| 2026-03-30 | Evert B. Schimmelpennink | President, CEO and Secretary | Buy | — | — |
| 2026-03-30 | Jeffrey P. George | Director | Buy | — | — |
| 2026-03-30 | Daniel R. Chevallard | Chief Financial Officer | Buy | — | — |
| 2026-01-06 | Marc Odrich | Chief Medical Officer | A | — | — |
| 2026-01-06 | Shawn Olsson | Chief Commercial Officer | A | — | — |
| 2026-01-06 | Daniel R. Chevallard | Chief Financial Officer | A | — | — |
| 2026-01-06 | Evert B. Schimmelpennink | President, CEO and Secretary | A | — | — |
| 2025-11-19 | Shawn Olsson | Chief Commercial Officer | MIXED | — | — |
| 2025-11-10 | JAMES W MCCOLLUM | Director | Buy | — | — |
| 2025-11-07 | Daniel R. Chevallard | Chief Financial Officer | Buy | — | — |
| 2025-10-02 | Versant Vantage II GP-GP, LLC | 10%+ Owner | Sell | — | — |
| 2025-09-22 | Versant Venture Capital VII, L.P. | 10%+ Owner | Sell | — | — |
| 2025-08-26 | Versant Venture Capital VI, L.P. | 10%+ Owner | Sell | — | — |
| 2025-08-19 | Versant Venture Capital VII, L.P. | 10%+ Owner | Sell | — | — |
| 2025-07-14 | Versant Venture Capital VI, L.P. | 10%+ Owner | Sell | — | — |
| 2025-07-01 | Versant Vantage II GP, L.P. | 10%+ Owner | Sell | — | — |
| 2025-06-20 | Versant Vantage II GP, L.P. | 10%+ Owner | Sell | — | — |
| 2025-06-12 | Versant Venture Capital VI, L.P. | 10%+ Owner | Sell | — | — |
| 2025-06-11 | Zachary Scheiner | Director | A | — | — |
| 2025-06-11 | Jeffrey P. George | Director | A | — | — |
| 2025-06-11 | JAMES W MCCOLLUM | Director | A | — | — |
| 2025-06-11 | Frederic Guerard | Director | A | — | — |
| 2025-06-11 | Shelley B Thunen | Director | A | — | — |
| 2025-06-11 | Kimberlee C Drapkin | Director | A | — | — |
| 2025-06-11 | RA Capital Nexus Fund II, L.P. | Director | A | — | — |
| 2025-04-09 | Shawn Olsson | Chief Commercial Officer | M | — | — |
| 2025-03-07 | Evert B. Schimmelpennink | President, CEO and Secretary | M | — | — |
| 2025-01-13 | Shawn Olsson | Chief Commercial Officer | A | — | — |
| 2025-01-13 | Daniel R. Chevallard | Chief Financial Officer | A | — | — |
| 2025-01-13 | Evert B. Schimmelpennink | President, CEO and Secretary | A | — | — |
| 2025-01-13 | Marc Odrich | Chief Medical Officer | A | — | — |
| 2024-12-17 | Shawn Olsson | Chief Commercial Officer | M | — | — |
| 2024-07-23 | Evert B. Schimmelpennink | President, CEO and Secretary | M | — | — |
| 2024-05-15 | Daniel R. Chevallard | Chief Financial Officer | Buy | — | — |
| 2024-05-14 | JAMES W MCCOLLUM | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,609,437 | — |
| — | 10%+ Owner | 2,299,292 | — |
| — | 10%+ Owner | 2,060,248 | — |
| — | 10%+ Owner | 1,898,092 | — |
| — | Director | 631,099 | — |
| — | President, CEO and Secretary | 77,289 | — |
| — | Chief Financial Officer | 12,886 | — |
| — | Director | 5,592 | — |
| — | Chief Commercial Officer | 4,733 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LENZ quote page; the site-wide leaderboard is on the insider transactions hub.